Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Feb;12(2):159-70.
doi: 10.1517/14728222.12.2.159.

Tissue-type plasminogen activator as a therapeutic target in stroke

Iordanis Gravanis  1 , Stella E Tsirka
Affiliations
Review

Tissue-type plasminogen activator as a therapeutic target in stroke

Iordanis Gravanis et al. Expert Opin Ther Targets. 2008 Feb.

Abstract

Background: Ischemic stroke is a leading cause of morbidity and mortality worldwide and recombinant human tissue-type plasminogen activator (tPA) is the prominent therapeutic among very few therapeutics used in its treatment. Due to complications attributed to the drug, most notably transformation of ischemia to hemorrhage, tPA is only used in a small number of ischemic stroke cases, albeit significantly more often in specialized stroke centers.

Objective: What are the mechanisms of tPA action and side effects in ischemic stroke, and can the knowledge about these mechanisms aid in making tPA a more efficacious and safe therapeutic or in developing alternative therapeutics?

Methods: tPA use and alternative/combination therapies in acute ischemic stroke treatment are summarized. The review focuses on literature concerning tPA neurotoxicity and its implications for further development of tPA as a stroke therapeutic.

Results/conclusion: Exogenously administered recombinant tPA and endogenous tPA have both turned into promising therapeutic targets for the stroke patient.

PubMed Disclaimer

References

    1. Rosamond W, Flegal K, Friday G, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–171. - PubMed
    1. Aoki N. Discovery of α2-plasmin inhibitor and its congenital deficiency. J Thromb Haemost. 2005;3:623–631. - PubMed
    1. Gallimore MJ. More on: discovery of α2-plasmin inhibitor and its congenital deficiency. J Thromb Haemost. 2006;4:284–285. - PubMed
    1. Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994;368:419–424. - PubMed
    1. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 1995;9:794–907. - PubMed

Publication types

MeSH terms

Substances